6:29 PM
 | 
Nov 05, 2012
 |  BC Extra  |  Company News

FDA posts pasireotide briefing documents

FDA reviewers said pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) is effective for treating Cushing's disease, but cautioned that the "efficacy results need to be considered in the context of the overall safety profile" of the somatostatin...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >